Host signaling pathways modulated by perinatal mesenchymal stem cells

Host signaling pathways modulated by perinatal mesenchymal stem cells (MSCs) refer to the complex network of intracellular signals in a recipient organism that are altered following the administration of MSCs derived from birth-associated tissues like the umbilical cord or placenta. These cells do not act on a single receptor but rather function as 'bioreactors' that release a broad spectrum of bioactive molecules, including TGF-β, PGE2, and indoleamine 2,3-dioxygenase (IDO), which collectively suppress pro-inflammatory pathways like NF-κB and MAPK while promoting regenerative pathways such as PI3K/Akt (Source: PubMed, PMC7065913). This multi-target modulation is particularly effective in treating systemic inflammation, autoimmune disorders, and tissue injury by shifting the host immune environment from a pro-inflammatory (M1) to an anti-inflammatory (M2) state (Source: Frontiers in Immunology, 2021). In clinical contexts, these pathways are critical for the therapeutic efficacy of MSCs in conditions like Graft-versus-Host Disease (GvHD) and acute respiratory distress syndrome (ARDS). However, because this 'target' represents a collection of biological processes rather than a discrete molecular entity, it presents significant challenges for pharmacological standardization and regulatory approval. The interaction between the MSC secretome and host signaling is highly context-dependent, influenced by the local microenvironment and the specific origin of the perinatal cells (Source: Stem Cell Research & Therapy, 2020). Consequently, while these pathways offer high therapeutic potential, they require sophisticated biomarker monitoring to ensure safety and efficacy.

Other names

Perinatal MSC-mediated signalingMesenchymal stem cell immunomodulatory pathwaysMSC paracrine signaling cascadesPerinatal MSC secretome-induced signaling

Perinatal MSCs modulate host signaling by secreting a variety of paracrine factors, including cytokines, growth factors, and extracellular vesicles (EVs), which bind to host cell receptors and trigger intracellular cascades such as the inhibition of NF-κB and activation of PI3K/Akt or STAT3 pathways.